Are we really curing cancer… or just managing it for a little longer?

In this compelling episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the uncomfortable truth behind many FDA-approved cancer drugs: they often provide only 2–3 months of life extension, with little to no improvement in quality of life.

🎯 What You’ll Learn:

• Why many cancer drugs are approved without long-term survival data
• The problem with “Fast Track” approvals and tumor shrinkage as a success metric
• How precision oncology uses multi-omics (RNA, DNA, immune, spatial biology) to guide care
• The difference between managing tumors and striving for durable remission
• How adaptive targeting, microdosing, and interventional delivery aim to reduce resistance and increase response
• What real-time biomarkers (ctDNA, immune signals, tumor microenvironment) tell us about treatment progress

📊 According to Envita’s data, patients mapped with this precision model show improved outcomes, better quality of life, and fewer side effects compared to conventional care — all without relying on “trial and error.”*
*(See Outcomes Disclaimer Below)

“Cancer treatment should aim for long-term remission — not just short-term control.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493